Polymorphisms in TOLL-like receptor genes and their roles in allergic asthma and atopy

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 5, Issue 1, 2011, Pages 45-56

  Kanagaratham, Cynthia ^a   Camateros, Pierre ^b   Flaczyk, Adam ^a   Radzioch, Danuta ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Airway hyperresponsiveness; Asthma; Atopy; Immunotherapeutics; Macrophages; Polymorphisms; TOLL like receptors

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE RECEPTOR; CHLOROQUINE; CORTICOSTEROID; CPG IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; HYDROXYCHLOROQUINE; IMO 2055; IMO 2125; LIGAND; MEPACRINE; MUTANT PROTEIN; MUTEIN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG;

AIRWAY; ALLERGIC ASTHMA; ATOPY; BRONCHUS HYPERREACTIVITY; CHRONIC INFLAMMATION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE EXPRESSION; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MACROPHAGE; MALARIA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; HUMANS; HYPERSENSITIVITY; MACROPHAGES; PATENTS AS TOPIC; POLYMORPHISM, GENETIC; RNA INTERFERENCE; TOLL-LIKE RECEPTORS;

EID: 79551648162     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221311794474874     Document Type: Review

References (132)

1. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988; 1(8595): 1129-1132.
2. Devenny A, Wassall H, Ninan T, Omran M, Khan SD, Russell G. Respiratory symptoms and atopy in children in Aberdeen: Questionnaire studies of a defined school population repeated over 35 years. BMJ 2004; 329(7464): 489-490.
3. Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120(5): S94-S138.
4. Duffy DL, Martin NG, Battistutta D, Hopper JL, Mathews JD. Genetics of asthma and hay fever in Australian twins. Am Rev Respir Dis 1990; 142(6 Pt 1): 1351-1358.
5. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008; 454(7203): 445-454.
6. Fukai H, Ogasawara Y, Migita O, Koga M, Ichikawa K, Shibasaki M, et al. Association between a polymorphism in cysteinyl leukotriene receptor 2 on chromosome 13q14 and atopic asthma. Pharmacogenetics 2004; 14(10): 683-690.
7. Hasegawa K, Tamari M, Shao C, Shimizu M, Takahashi N, Mao XQ, et al. Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004; 115(4): 295-301.
8. Hirota T, Obara K, Matsuda A, Akahoshi M, Nakashima K, Hasegawa K, et al. Association between genetic variation in the gene for death-associated protein-3 (DAP3) and adult asthma. J Hum Genet 2004; 49(7): 370-375.
9. Thompson MD, Takasaki J, Capra V, Rovati GE, Siminovitch KA, Burnham WM, et al. G-protein-coupled receptors and asthma endophenotypes: The cysteinyl leukotriene system in perspective. Mol Diagn Ther 2006; 10(6): 353-366.
10. Bosse Y, Hudson TJ. Toward a comprehensive set of asthma susceptibility genes. Annu Rev Med 2007; 58: 171-184.
11. Sterk PJ, Bel EH. Bronchial hyperresponsiveness: The need for a distinction between hypersensitivity and excessive airway narrowing. Eur Respir J 1989; 2(3): 267-274.
12. Hardy CC, Robinson C, Tattersfield AE, Holgate ST. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med 1984; 311(4): 209-213.
13. Thomson NC, Roberts R, Bandouvakis J, Newball H, Hargreave FE. Comparison of bronchial responses to prostaglandin F2 alpha and methacholine. J Allergy Clin Immunol 1981; 68(5): 392-398.
14. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315(8): 480-484.
15. O'Byrne PM, Inman MD. Airway hyperresponsiveness. Chest 2003; 123(3): 411S-16S.
16. O'Byrne PM, Ryan G, Morris M, McCormack D, Jones NL, Morse JL, et al. Asthma induced by cold air and its relation to nonspecific bronchial responsiveness to methacholine. Am Rev Respir Dis 1982; 125(3): 281-285.
17. Becker S, Fenton MJ, Soukup JM. Involvement of microbial components and toll-like receptors 2 and 4 in cytokine responses to air pollution particles. Am J Respir Cell Mol Biol 2002; 27(5): 611-618.
18. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999; 104(8): 1001-1006.
19. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: A method and clinical survey. Clin Allergy 1977; 7(3): 235-243.
20. Hao K, Chen C, Wang B, Yang J, Fang Z, Xu X. Familial aggregation of airway responsiveness: A community-based study. Ann Epidemiol 2005; 15(10): 737-743.
21. Longo G, Strinati R, Poli F, Fumi F. Genetic factors in nonspecific bronchial hyperreactivity. An epidemiologic study. Am J Dis Child 1987; 141(3): 331-334.
22. Hopp RJ, Bewtra AK, Biven R, Nair NM, Townley RG. Bronchial reactivity pattern in nonasthmatic parents of asthmatics. Ann Allergy 1988; 61(3): 184-186.
23. De Sanctis GT, Merchant M, Beier DR, Dredge RD, Grobholz JK, Martin TR, et al. Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. Nat Genet 1995; 11(2): 150-154.
24. Ackerman KG, Huang H, Grasemann H, Puma C, Singer JB, Hill AE, et al. Interacting genetic loci cause airway hyperresponsiveness. Physiol Genomics 2005; 21(1): 105-111.
25. Whitehead GS, Walker JK, Berman KG, Foster WM, Schwartz DA. Allergen-induced airway disease is mouse strain dependent. Am J Physiol Lung Cell Mol Physiol 2003; 285(1): L32-L42.
26. Camateros P, Marino R, Fortin A, Martin JG, Skamene E, Sladek R, et al. Identification of novel chromosomal regions associated with airway hyperresponsiveness in recombinant congenic strains of mice. Mamm Genome 2010; 21(1-2): 28-38.
27. Finkelman FD, Vercelli D. Advances in asthma, allergy mechanisms, and genetics in 2006. J Allergy Clin Immunol 2007; 120(3): 544-550.
28. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320(5): 271-277.
29. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141(2): 471-501.
30. Osterholzer JJ, Milam JE, Chen GH, Toews GB, Huffnagle GB, Olszewski MA. Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans. Infect Immun 2009; 77(9): 3749-3758.
31. Holt PG, Oliver J, Bilyk N, McMenamin C, McMenamin PG, Kraal G, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993; 177(2): 397-407.
32. Strickland DH, Thepen T, Kees UR, Kraal G, Holt PG. Regulation of T-cell function in lung tissue by pulmonary alveolar macrophages. Immunology 1993; 80(2): 266-272.
33. Lun SW, Wong CK, Ko FW, Hui DS, Lam CW. Expression and functional analysis of toll-like receptors of peripheral blood cells in asthmatic patients: Implication for immunopathological mechanism in asthma. J Clin Immunol 2009; 29(3): 330-342.
34. Rosenwasser LJ. New immunopharmacologic approaches to asthma: Role of cytokine antagonism. J Allergy Clin Immunol 2000; 105(2 Pt 2): S586-S591.
35. Gosset P, Tillie-Leblond I, Oudin S, Parmentier O, Wallaert B, Joseph M, et al. Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors. J Allergy Clin Immunol 1999; 103(2 Pt 1): 289-297.
36. Sugiura H, Ichinose M. Oxidative and nitrative stress in bronchial asthma. Antioxid Redox Signal 2008; 10(4): 785-797.
37. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. Respir Med 2002; 96: S9-S15.
38. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23: 901-944.
39. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 20: 86(6): 973-983.
40. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4): 783-801.
41. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388(6640): 394-397.
42. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: A trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27(8): 352-357.
43. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17(1): 1-14.
44. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348(5): 1079-1090.
45. Liang S, Hosur KB, Lu S, Nawar HF, Weber BR, Tapping RI, et al. Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer. J Immunol 2009; 182(5): 2978-2985.
46. Mizel SB, Honko AN, Moors MA, Smith PS, West AP. Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J Immunol 2003; 170(12): 6217-6223.
47. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168(2): 554-561.
48. Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004; 31(3): 358-364.
49. Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR, Tetley TD, et al. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am J Respir Cell Mol Biol 2004; 31(2): 241-245.
50. Fernandez S, Jose P, Avdiushko MG, Kaplan AM, Cohen DA. Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists. J Immunol 2004; 172(4): 2613-2620.
51. Applequist SE, Wallin RP, Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol 2002; 14(9): 1065-1074.
52. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008; 36: D480-D484.
53. Long EM, Millen B, Kubes P, Robbins SM. Lipoteichoic acid induces unique inflammatory responses when compared to other toll-like receptor 2 ligands. PLoS One 2009; 4(5): e5601.
54. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13(7): 933-940.
55. Weigt H, Nassenstein C, Tschernig T, Muhlradt PF, Krug N, Braun A. Efficacy of macrophage-activating lipopeptide-2 combined with interferon-gamma in a murine asthma model. Am J Respir Crit Care Med 2005; 172(5): 566-572.
56. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005; 35(1): 282-289.
57. Fuchs B, Braun A. Modulation of asthma and allergy by addressing toll-like receptor 2. J Occup Med Toxicol 2008; (3 Suppl 1): S5.
58. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16(1): 3-9.
59. Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH, et al. Cutting edge: Activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004; 172(5): 2739-2743.
60. Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB, et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003; 33(10): 2717-2726.
61. Patel M, Xu D, Kewin P, Choo-Kang B, McSharry C, Thomson NC, et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005; 174(12): 7558-7563.
62. Wu Q, Martin RJ, Lafasto S, Efaw BJ, Rino JG, Harbeck RJ, et al. Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance. Am J Respir Crit Care Med 2008; 177(7): 720-729.
63. Revets H, Pynaert G, Grooten J, De BP. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 2005; 174(2): 1097-1103.
64. Bjornvold M, Munthe-Kaas MC, Egeland T, Joner G, Dahl-Jørgensen K, Njølstad PR, et al. A TLR2 polymorphism is associated with type 1 diabetes and allergic asthma. Genes Immun 2009; 10(2): 181-187.
65. Bortolatto J, Borducchi E, Rodriguez D, Keller AC, Faquim-Mauro E, Bortoluci KR, et al. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: Role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis. Clin Exp Allergy 2008; 38(10): 1668-1679.
66. Dong L, Li H, Wang S, Li Y. Different doses of lipopolysaccharides regulate the lung inflammation of asthmatic mice via TLR4 pathway in alveolar macrophages. J Asthma 2009; 46(3): 229-233.
67. Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA 2009; 106(44): 18704-18709.
68. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301(5633): 640-643.
69. Siwiec J, Zaborowski T, Jankowska O, Wojas-Krawczyk K, Krawczyk P, Milanowski J. Evaluation of Th1/Th2 lymphocyte balance and lipopolysaccharide receptor expression in asthma patients. Pneumonol Alergol Pol 2009; 77(2): 123-130.
70. Singh AM, Busse WW. Asthma exacerbations. 2: A etiology. Thorax 2006; 61(9): 809-816.
71. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089-4097.
72. Yang M, Kumar RK, Foster PS. Pathogenesis of steroid-resistant airway hyperresponsiveness: Interaction between IFN-gamma and TLR4/MyD88 pathways. J Immunol 2009; 182(8): 5107-5115.
73. Schaumann F, Muller M, Braun A, Luettig B, Peden DB, Hohlfeld JM, et al. Endotoxin augments myeloid dendritic cell influx into the airways in patients with allergic asthma. Am J Respir Crit Care Med 2008; 177(12): 1307-1313.
74. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25(2): 187-191.
75. Fageras BM, Hmani-Aifa M, Lindstrom A, Jenmalm MC, Mai XM, Nilsson L, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114(3): 561-567.
76. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20(5): 976-983.
77. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: Distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003; 170(4): 1625-1629.
78. Chun E, Lee SH, Lee SY, Shim EJ, Cho SH, Min KU, et al. Tolllike receptor expression on peripheral blood mononuclear cells in asthmatics: Implications for asthma management. J Clin Immunol 2010; 30(3): 459-464.
79. Kormann MS, Depner M, Hartl D, Klopp N, Illig T, Adamski J, et al. Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 2008; 122(1): 86-92.
80. Hoffjan S, Stemmler S, Parwez Q, Petrasch-Parwez E, Arinir U, Rohde G, et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005; 6: 34.
81. Tantisira K, Klimecki WT, Lazarus R, Palmer LJ, Raby BA, Kwiatkowski DJ, et al. Toll-like receptor 6 gene (TLR6): Singlenucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004; 5(5): 343-346.
82. Roponen M, Yerkovich ST, Hollams E, Sly PD, Holt PG, Upham JW. Toll-like receptor 7 function is reduced in adolescents with asthma. Eur Respir J 2010; 35(1): 64-71.
83. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007; 6(4): 223-235.
84. Camateros P, Kanagaratham C, Henri J, Sladek R, Hudson TJ, Radzioch D. Modulation of the allergic asthma transcriptome following resiquimod treatment. Physiol Genomics 2009; 38(3): 303-318.
85. Camateros P, Tamaoka M, Hassan M, Marino R, Moisan J, Marion D, et al. Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am J Respir Crit Care Med 2007; 175(12): 1241-1249.
86. Moisan J, Camateros P, Thuraisingam T, Marion D, Koohsari H, Martin P, et al. TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol 2006; 290(5): L987-L995.
87. Haagerup A, Borglum AD, Binderup HG, Kruse TA. Fine-scale mapping of type I allergy candidate loci suggests central susceptibility genes on chromosomes 3q, 4q and Xp. Allergy 2004; 59(1): 88-94.
88. Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, Tan Q, et al. Atopic dermatitis - a total genome-scan for susceptibility genes. Acta Derm Venereol 2004; 84(5): 346-352.
89. Brasch-Andersen C, Moller MU, Haagerup A, Vestbo J, Kruse TA. Evidence for an asthma risk locus on chromosome Xp: A replication linkage study. Allergy 2008; 63(9): 1235-1238.
90. Moller-Larsen S, Nyegaard M, Haagerup A, Vestbo J, Kruse TA, Borglum AD. Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax 2008; 63(12): 1064-1069.
91. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007; 21(6): 387-401.
92. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007; 35(Pt 6): 1461-1467.
93. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptorassociated factor (TRAF)6. J Exp Med 2000; 192(4): 595-600.
94. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3(2): 196-200.
95. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, et al. Cutting edge: Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88- dependent signaling pathway. J Immunol 2000; 164(2): 554-557.
96. Muller T, Hamm S, Bauer S. TLR9-mediated recognition of DNA. Handb Exp Pharmacol 2008; (183): 51-70.
97. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
98. Choudhury BK, Wild JS, Alam R, Klinman DM, Boldogh I, Dharajiya N, et al. In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol 2002; 169(10): 5955-5961.
99. Janssen EM, Wauben MH, Nijkamp FP, van EW, van Oosterhout AJ. Immunomodulatory effects of antigen-pulsed macrophages in a murine model of allergic asthma. Am J Respir Cell Mol Biol 2002; 27(2): 257-264.
100. Vissers JL, van Esch BC, Jeurink PV, Hofman GA, van Oosterhout AJ. Stimulation of allergen-loaded macrophages by TLR9-ligand potentiates IL-10-mediated suppression of allergic airway inflammation in mice. Respir Res 2004; 5: 21.
101. Campbell JD, Cho Y, Foster ML, Kanzler H, Kachura MA, Lum JA, et al. CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. J Clin Invest 2009; 119(9): 2564-2576.
102. Suzuki K, Suda T, Naito T, Ide K, Chida K, Nakamura H. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am J Respir Crit Care Med 2005; 171(7): 707-713.
103. Wieland CW, Florquin S, van der Poll T. Toll-like receptor 9 is not important for host defense against Haemophilus influenzae. Immunobiology 2010; 215(11): 910-914.
104. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007; 132(6): 1962-1966.
105. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408(6813): 740-745.
106. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98(16): 9237-9242.
107. Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, Kwiatkowski DJ, et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): Frequencies, pairwise linkage disequilibrium, and haplotypes in three US ethnic groups and exploratory case-control disease association studies. Genomics 2003; 81(1): 85-91.
108. Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M, et al. An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 2004; 34(2): 177-183.
109. Berghofer B, Frommer T, Konig IR, Ziegler A, Chakraborty T, Bein G, et al. Common human Toll-like receptor 9 polymorphisms and haplotypes: Association with atopy and functional relevance. Clin Exp Allergy 2005; 35(9): 1147-1154.
110. Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, et al. Long-term activation of TLR3 by poly(I: C) induces inflammation and impairs lung function in mice. Respir Res 2009; 10: 43.
111. Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol 2007; 179(2): 1080-1087.
112. Bachar O, Adner M, Uddman R, Cardell LO. Toll-like receptor stimulation induces airway hyper-responsiveness to bradykinin, an effect mediated by JNK and NF-kappa B signaling pathways. Eur J Immunol 2004; 34(4): 1196-1207.
113. Nakaar, V., Huang, Y., Powell, T. Novel polypeptide ligands for toll-like receptor 2 (TLR2). US20090028889 (2009).
114. Aderem, A., Hayashi, F., Smith, Kelly D., Underhill, D. M., Ozinsky, A. Toll-like receptor 5 ligands and methods of use. US20050147627 (2005).
115. Kandimalla, E., Putta, M., Yu, D., Bhagat, L., Wang, D., Agrawal, S. Synthetic agonists of TLR9. US20080292648 (2008).
116. Upadhyay, S., Sharma, A., Sharma, A., Rajagopal, V., Datla, P., Bellary, A., Singh, S. P. Carbohydrate based toll-like receptor (TLR) antagonists. US20090215710 (2009).
117. Quarcoo D, Weixler S, Joachim RA, Stock P, Kallinich T, Ahrens B, et al. Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin Exp Allergy 2004; 34(8): 1314-1320.
118. Hawkins, L. D., Ishizaka, S. T. Immunomodulatory compounds and methods of use thereof. US20070027111 (2007).
119. Krieg, A.M., Schetter, C., Bratzler, R. L.,Vollmer, J., Jurk, M., Bauer, S., Methods and products for enhancing immune responses using imidazoquinoline compounds. US20060188913 (2006).
120. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL, et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995; 15(6): 537-545.
121. Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000; 165(10): 5552-5557.
122. Fenton, M. J., Vogel, S. N., Toshchakov, V. Selective inhibition of TLR4 signaling. US20100069297 (2010).
123. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Chloroquine as a steroid sparing agent for asthma. Cochrane Database Syst Rev 2003; (4): CD003275.
124. Charous BL. Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. Ann Allergy 1990; 65(1): 53-58.
125. Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. J Allergy Clin Immunol 1998; 102(2): 198-203.
126. Chen, J., Eisen, H. N., Ge, Q. RNAi-based therapeutics for allergic rhinitis and asthma. US20060058255 (2006).
127. Kandimalla, E., Putta, M., Bhagat, L., Wang, D., Yu, D., Zhu, F. G., Agrawal, S. Modulation of toll-like receptor 7 expression by antisense oligonucleotides. US20100041734 (2010).
128. Duffy, K. E., Cunningham, M., M'bow, M. L., Sarisky, R. T. TLR3 Glycosylation site muteins and methods of use. US20070203064 (2007).
129. Leung DY, Szefler SJ. New insights into steroid resistant asthma. Pediatr Allergy Immunol 1998; 9(1): 3-12.
130. Von Stein, O., Hellström, K. Method for the prevention, treatment and/or alleviation of an inflammatory disease. US20100004319 (2010).
131. Simon HU, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 2003; 58(12): 1250-1255.
132. Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009; 60: 279-291.